2022 AAPM 64th Annual Meeting
Back to session list

Session Title: New IAEA Programs and Projects on Radiopharmaceutical Therapy
Question 1: 68Ga PET used as an imaging surrogate for therapies such as 177Lu peptide receptor radionuclide therapy is not typically used for predictive dosimetry because
Reference:Eberlein U, Cremonesi M, Lassmann M. Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive? J Nucl Med. 2017 Sep;58(Suppl 2):97S-103S.
Choice A:Ga-68 has a long half-life
Choice B:of the superior spatial resolution and sensitivity of PET compared with SPECT
Choice C:Ga-68 has a half-life of only 68 minutes
Choice D:Ga-68 is a non-pure positron emitter
Question 2: Partial volume correction to compensate for SPECT and PET resolution effects is especially important:
Reference:Dewaraja YK, Frey EC, Sgouros G, Brill AB, Roberson P, Zanzonico PB, Ljungberg M. MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med. 2012 Aug;53(8):1310-25
Choice A:when performing dosimetry of large organs such as the liver
Choice B:for beta emitters
Choice C:for dosimetry performed after a therapy cycle
Choice D:when performing tumor dosimetry
Question 3: How many scientific and technical publications the IAEA has produced
Choice A:500
Choice B:5000
Choice C:7000
Choice D:more than 9000
Question 4: What is the IAEA’s primary mechanism for transferring nuclear technology to Member States
Choice A:Technical corporation programmes
Choice B:Scientific publications
Choice C:Software
Choice D:Guidelines
Question 5: Which absorbed-dose metric is considered the most relevant to understand the relationship between absorbed dose and deterministic tissue effects?
Reference:Dosimetry for Radiopharmaceutical Therapy, International Atomic Energy Agency, Vienna (Austria). Sgouros G, Bolch WE, Chiti A, et al. ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy. Journal of the ICRU. 2021;21(1):1-212.
Choice A:The mean absorbed dose to the whole body
Choice B:The absorbed dose to the tissue or organ that is responsible for the biological effect
Choice C:The administered activity combined with literature data on absorbed dose per activity from previous patient cohorts
Choice D:The effective dose, as previously reported for the radiopharmaceutical
Question 6: Which components of SPECT-based dosimetry of, for example, the kidneys in 177Lu DOTA-TATE therapy with imaging at three time points, are considered to contribute with the largest source of uncertainty?
Reference:Gear JI, Cox MG, Gustafsson J, Gleisner KS, Murray I, Glatting G, Konijnenberg M, Flux GD. EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. Eur J Nucl Med Mol Imaging. 2018;45(13) Dosimetry for Radiopharmaceutical Therapy, International Atomic Energy Agency, Vienna (Austria).
Choice A:Limited spatial resolution of SPECT and delineation of organ VOIs, affecting VOI counts and the estimated volume
Choice B:Limited count rate and image noise, affecting the VOI counts
Choice C:Radionuclide data and S-values, affecting the absorbed-dose calculation
Choice D:Background and overlap correction, affecting the VOI counts for the organ
Back to session list